Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 1214 results

Media Release / Dec 12, 2016
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…
Media Release / Dec 09, 2016
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone …
Media Release / Dec 08, 2016
Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the…
Media Release / Dec 07, 2016
Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
The European Commission approved Lucentis to treat patients for visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular…
Media Release / Dec 06, 2016
Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC[1] Patients with…
Media Release / Dec 05, 2016
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®
ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients[1] The Tasigna TFR trials, including ENESTop, demonstrate our continued…
Media Release / Dec 05, 2016
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
Findings across six countries and four continents showed a reduction in quality of life for majority (71%) of patients living with myeloproliferative neoplasms (MPNs)[1] Patients…
Media Release / Dec 05, 2016
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1] Interim data in over…
Media Release / Dec 04, 2016
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T…
Media Release / Dec 03, 2016
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
SEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy SEG101 is a potential new disease-…

‹ Previous page
1
…
95
96
97
98
99
100
101
…
122
› Next page